CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02657889
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:53.815428+00:00
- Published At
- 2020-02-11T00:00:00+00:00
- Record Updated At
- 2022-12-01
- Results Posted At
- 2020-02-11
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Neoplasms", "Triple Negative Breast Cancer", "Ovarian Cancer", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Stage IV Breast Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-12-01"- protocolSection.identificationModule.nctId
"NCT02657889"- protocolSection.identificationModule.officialTitle
"Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-02-11"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.